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Abstract
Objectives. To examine the relation between serum C1q levels and
blood type-1 interferon signature (type-1 IFN signature) in active
pulmonary tuberculosis (APTB) and to determine whether
combined measurement of serum C1q and type-1 IFN signature
may add to the diagnosis of QuantiFERON-positive (QFT+) patients
with uveitis of unknown cause. Methods. C1q was determined
(ELISA) in serum from two distinct Indonesian cohorts, and in
total, APTB (n = 72), QFT+ uveitis of unknown aetiology (n = 58),
QFT uveitis (n = 51) patients and healthy controls (HC; n = 73)
were included. The type-1 IFN signature scores were previously
determined. Results. Serum C1q was higher in APTB than HC
(P < 0.001). APTB patients with uveitis had higher serum C1q than
APTB patients without uveitis (P = 0.0207). Serum C1q correlated
inversely with type-1 IFN signature scores in APTB (P = 0.0036,
r2 = 0.3526), revealing that these biomarkers for active TB disease
can be mutually exclusive. Stratification of QFT+ patients with
uveitis of unknown cause, by serum C1q and type-1 IFN signature,
yielded four groups with different likelihood of suffering from
active TB uveitis. Conclusion. Serum C1q is elevated in APTB,
especially in those cases with uveitis. We propose that combined
measurement of blood type-1 IFN signature and serum C1q may
provide added value in the diagnosis of active TB disease.
Combined measurement of type-1 IFN signature and serum C1q in
QFT+ patients without signs of active TB disease, but suffering
from uveitis of unknown cause, may be of help to identify cases
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with low or high likelihood of having active TB uveitis, which may
facilitate clinical management decisions.
Keywords: C1q, complement, extrapulmonary tuberculosis,
QuantiFERON, type-1 interferon signature, uveitis
INTRODUCTION
Tuberculosis (TB) is an airborne infectious disease
caused by Mycobacterium tuberculosis (Mtb)
bacilli.1 To date, TB remains a major global health
threat and leading cause of death from a single
infectious agent. The World Health Organization
(WHO) estimates that a quarter of the world’s
population is infected with Mtb. Most of these
individuals remain asymptomatically latently
infected (LTBI), while ~ 5–10% develop clinically
active TB disease during their lifetime.2 The WHO
estimated that ~ 10 million new TB cases emerged
in 2018, with increasing TB notifications especially
in India and Indonesia.2
Although primarily a pulmonary pathogen, Mtb
can disseminate from the primary focus of
infection throughout the body via blood and
lymphatic system, infecting other organs,
including the eyes.3 Ocular involvement has a
prevalence between ~1.5 and 18% in pulmonary
TB patients, but may also occur without
pulmonary involvement and/or other signs of
TB.4–9 Timely diagnosis of active TB infection is
crucial as it contributes to swift treatment
initiation and thereby pathogen eradication,
minimising disease burden and curtailing Mtb
transmission.2
Sputum smear microscopy and culture-based
methods are the standard diagnostic laboratory
tests for active TB, but PCR-based techniques are
also used to directly identify the pathogen.10–12 All
these tests are hampered by sensitivity and/or
specificity issues and are often time consuming.
Initiation of an adaptive immune response after
Mtb exposure usually results in memory T-helper
(Th)1-cell formation. These Th1 cells become
activated upon re-exposure to Mtb antigens, which
is typically exploited by in vitro interferon gamma
(IFN-c) release assays (e.g. QuantiFERON-TB Gold
test; QFT) or tuberculin skin test (TST). Although
these tests provide evidence of existing
immunological memory towards Mtb, by no means
do they discriminate between active TB disease and
LTBI. The diagnosis of ocular TB is especially difficult
to achieve because access to intraocular tissues is
limited. Moreover, only a few Mtb bacilli may
invade the intraocular environment, where they
especially infect the retinal pigment epithelium
(RPE).13–15 Yet, rapid initiation of anti-tuberculosis
treatment (ATT) in TB-associated uveitis is important
as substantial vision loss, or even blindness, can
occur if left untreated.16,17 Especially in high TB-
endemic areas, the association between QFT
positivity and uveitis might be coincidental.
Therefore, it is important to identify those QFT+
uveitis patients suffering from active TB disease,
especially when there are no other signs of active TB
infection. Consequently, QFT+ uveitis patients with
LTBI could be prevented from undergoing
overzealous ATT treatment. Altogether, this
indicates the urgent need for biomarkers that
discriminate active TB from LTBI, especially in those
areas where TB is highly endemic.
Several reports have indicated that patients
suffering from active TB disease display a
peripheral blood transcriptome that is highly
enriched for type-1 IFN-stimulated genes (ISGs).18–
21 In line with this, we recently reported a whole
blood transcriptional signature of 10 ISGs (type-1
IFN signature) that was associated with active
pulmonary TB (APTB) in Indonesian patients. In
addition, we demonstrated that this type-1 IFN
signature stratified QFT+ patients with uveitis of
undetermined cause into distinct groups. We
proposed that type-1 IFN signature-positive
patients were more likely to suffer from active TB-
associated uveitis.22 Furthermore, increased
expression of mRNA for complement component
C1q has been described in peripheral blood cells
from active TB patients.23–25 More recently,
Lubbers et al. reported elevated serum C1q levels
in APTB as compared to LTBI, healthy controls,
and disease controls.23 Consequently, serum C1q
was proposed as biomarker to detect active TB
disease.23 However, Lubbers et al. did not explore
serum C1q levels in relation to TB-associated
uveitis. Also, no correlations with peripheral
blood type-1 IFN signatures were determined.
However, the latter is of special interest as C1q
has been shown to attenuate IFN-a production by
peripheral blood mononuclear cells.26,27
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Therefore, in our current study, we examined the
following: (1) serum C1q levels in two
independently collected cohorts of Indonesian
patients with APTB and healthy controls, (2) the
correlation between serum C1q levels and the type-
1 IFN signature score in active TB and systemic
autoimmune diseases [primary Sj€ogren’s syndrome
(pSS), systemic lupus erythematosus (SLE) and
systemic sclerosis (SSc)], and (3) whether the
combination of serum C1q level and peripheral
blood type-1 IFN signature may improve
stratification of QFT+ patients with uveitis of
unknown cause, into groups highly likely, or less
likely, to suffer from active TB-associated uveitis.
RESULTS
Increased serum C1q levels in active
pulmonary TB patients
In both independently collected Indonesian
cohorts, serum C1q levels were significantly
increased in APTB patients (P < 0.001) as
compared to healthy controls (Figure 1).
Furthermore, serum C1q levels were significantly
increased in APTB patients from cohort 1
(P = 0.0305) as compared to cohort 2, while no
statistically significant difference in serum C1q
level was observed between the healthy control
groups (Figure 1). The capacity of serum C1q to
discriminate APTB from healthy controls was
analysed using receiver operating characteristic
(ROC) curve analysis on all APTB cases (n = 72)
versus all healthy controls (n = 73) and revealed
an area under the curve of 0.786 (P < 0.001; 95%
CI 0.712–0.859; Figure 2). Diagnostic performance,
as calculated by maximum Youden’s index,
revealed a sensitivity of 65.3% and specificity of
79.5%, when a cut-off value for serum
complement C1q of ≥ 271.1 µg mL1 was used
(Supplementary table 2).
Inverse correlation between serum C1q
levels and peripheral blood type-1 IFN
signature scores in active pulmonary TB
patients
In APTB patients (cohort 1, n = 22), serum C1q
levels displayed a significant inverse correlation
with the type-1 IFN signature scores (r2 = 0.3526;
P = 0.0036, Figure 3a). Substantial subsets of
patients with pSS, SLE and SSc also display a
positive type-1 IFN signature.28–31 Therefore, to
determine whether the inverse correlation
between serum C1q and peripheral blood type-1
IFN gene signature might be TB specific or
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Figure 1. Increased serum C1q levels in active pulmonary tuberculosis
(APTB). Comparison of serum C1q levels in APTB patients and healthy
controls from Indonesian cohort 1 (left, APTB n = 22, healthy controls
n = 23) and Indonesian cohort 2 (right, APTB n = 50, healthy controls
n = 50). APTB, active pulmonary tuberculosis; HC, healthy control.
Horizontal lines represent the group mean, and error bars indicate the
95% confidence interval (CI). Statistical analysis was performed on the
transformed data set in GraphPad Prism 5.0, and Welch’s t-test was
used to compare groups. *P < 0.05, ***P < 0.001.
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Figure 2. Receiver operating characteristics curve analysis of the
ability of serum C1q to distinguish APTB patients (cohort 1 + 2;
n = 72) from healthy controls (cohort 1 + 2; n = 73). Statistical
analysis was performed on the transformed data set in SPSS 25.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
2020 | Vol. 9 | e1196
Page 3
B Schrijver et al. Serum C1q in active pulmonary tuberculosis and QuantiFERON+ uveitis
represents a more general phenomenon, we also
determined the relation between serum C1q
levels and peripheral blood type-1 IFN signature
scores in pSS, SLE and SSc patients. Serum C1q
did not show any correlation with the
peripheral blood type-1 IFN signature scores in
any of these systemic autoimmune diseases
(Supplementary figure 1).
On the basis of all Indonesian healthy controls
(n = 73, cohorts 1 and 2), the upper limit of the
95% reference range was used as a cut-off value
for serum C1q levels. This yielded a cut-off value
of 2.57 (log (C1q µg mL1), indicated by the
horizontal line in Figure 3. We also applied a log
transformation on the previously reported type-1
IFN signature score cut-off value for positivity,22
yielding a value of 1.31, as indicated by the
vertical line in Figure 3. This generated four
quadrants based on serum C1q and type-1 IFN
signature score. Most importantly, application of
these quadrants clearly demonstrated that
although both increased serum C1q level and a
positive blood type-1 IFN signature have been
suggested as potential biomarker for active TB,
they can be mutually exclusive [Figure 3a:
quadrants I (elevated serum C1q and negative
type-1 IFN signature score) and III (normal serum
C1q and positive type-1 IFN signature score)].
Twenty out of 23 (87%) healthy controls located
to quadrant IV (normal serum C1q and negative
type-1 IFN gene signature; Figure 3b), while none
of the APTB cases located to this quadrant
(Figure 3a).
Increased serum C1q levels in QFT+ patients
with uveitis of unknown cause
C1q levels were significantly elevated in serum from
QFT+ patients with uveitis of unknown aetiology
(n = 58) as compared to QFT uveitis patients
(P < 0.001) and healthy controls (P < 0.001). Serum
C1q levels were comparable between QFT uveitis
patients and healthy controls (Figure 4).
Comparison between infectious and non-infectious
uveitis within the QFT uveitis group revealed no
difference in serum C1q levels (Figure 5a).
Interestingly, APTB patients with uveitis displayed
significantly higher serum C1q levels than APTB
patients without uveitis (P = 0.0207; Figure 5b).
Furthermore, APTB patients with uveitis had
significantly (P < 0.001) elevated serum C1q levels as
compared to QFT patients suffering from uveitis
because of infection with the obligate intracellular
parasite Toxoplasma gondii. Serum C1q levels in
Toxoplasmosis-associated uveitis patients were
comparable to levels in healthy controls (Figure 5c).
The combination of serum C1q and
peripheral blood type-1 IFN signature
distinguishes four distinct groups within
QFT+ uveitis patients
Applying the combination of serum C1q and the
type-1 IFN signature score cut-off values to the
QFT+ patients with uveitis of unknown cause
(n = 58) differentiated these patients into four
distinct groups (Figure 6). The majority of patients
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Figure 3. Correlation between serum C1q levels and whole blood transcriptional signature score, consisting of 10 type-1 interferon-stimulated
genes (type-1 IFN signature). The vertical line represents the previously reported22 type-1 IFN signature score cut-off value for active TB. The
horizontal line represents the serum C1q cut-off value based on the 95% reference interval for healthy controls (cohort 1 + 2; n = 73). (a)
Inverse correlation between serum C1q level and type-1 IFN signature score in APTB patients (cohort 1; n = 22). None of the patients located to
the left lower quadrant IV (normal serum C1q and a negative type-1 IFN signature). (b) No correlation between serum C1q levels and type-1 IFN
signature score in healthy controls (cohort 1, n = 23). Twenty of the 23 healthy controls located to the lower left quadrant IV (normal serum C1q
and a negative type-1 IFN signature). Statistical analysis was performed in GraphPad Prism 5.0, and correlation coefficient was determined with
Pearson’s r test.
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(n = 30; 52%) located to quadrant IV (normal
serum C1q and a negative type-1 IFN signature),
17 patients (29%) located to quadrant III (normal
serum C1q and a positive type-1 IFN signature), six
patients (10%) located to quadrant II (elevated
serum C1q and a positive type-1 IFN signature),
and five patients (9%) located to quadrant I
(elevated serum C1q and a negative type-1 IFN
signature).
DISCUSSION
In our current study, we established an association
between APTB (with or without uveitis) and
elevated serum C1q levels in two, independently
collected, Indonesian cohorts. ROC analysis
displayed the diagnostic value of serum C1q.
Serum C1q diagnostic performance, as calculated
by maximum Youden’s index (0.4473), revealed a
sensitivity of 65.3% and specificity of 79.5% to
discriminate APTB patients from geographically
matched healthy controls. These findings confirm
the previous study by Lubbers et al. that reported
increased serum C1q levels in APTB patients from
distinct geographical locations (Italy, Gambia,
Korea and South Africa) as compared to
geographically matched healthy controls, LTBI and
clinically relevant diseases (e.g. sarcoidosis, leprosy
and pneumonia).23 Our study is limited in the
sense that not all included healthy controls were
examined for the presence of LTBI, which could
have served as a separate control group. However,
equal serum C1q levels in LTBI and healthy
controls have previously been observed.23
Therefore, our data support the notion that
elevated serum C1q measurement may provide
added value in the diagnosis of active TB
infections.
We, and others, previously demonstrated that
APTB is associated with overexpression of ISGs in
peripheral blood cells and that this may represent
a biomarker for active TB, progression from
LTBI to active TB, or to monitor treatment
efficacy.18–20,22 Interestingly, associations between
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Figure 4. Increased serum C1q levels are associated with
QuantiFERON-Tb Gold (QFT)-positive uveitis of unknown cause.
Comparison of serum C1q levels in QFT+ patients with uveitis of
unknown cause (cohort 1; n = 58), QFT patients with uveitis (cohort
1; n = 51) and healthy controls (cohort 1 + 2; n = 73). UV, uveitis.
Horizontal lines represent the group mean, and error bars indicate
the 95% CI. Statistical analysis was performed on the transformed
data set in SPSS 25, and multiple comparison was performed by
analysis of variance (ANOVA) followed by Dunnett’s T3 post hoc
testing. ***P < 0.001.
(b)(a)
****
(c)
APTB
No UVWith UV
QFT- UV
Infectious non-Infectious
HC APTB UV Tox UV
C
1q
 μ
g 
m
L–
1  
C
1q
 μ
g 
m
L–
1 
C
1q
 μ
g 
m
L–
1  
***
500
400
300
200
100
0
1200
1000
800
600
400
200
0
1200
1000
800
600
400
200
0
Figure 5. Increased serum C1q levels in APTB patients with uveitis. (a) Comparison of serum C1q levels between infectious and non-infectious
uveitis amongst QFT patients (cohort 1; n = 51). (b) Comparison of serum C1q levels in APTB patients with uveitis (cohort 1; n = 12) and APTB
patients without uveitis (cohort 1; n = 10). (c) Comparison between serum C1q levels in APTB patients with uveitis (cohort 1; n = 12), QFT
patients with Toxoplasmosis gondii-associated uveitis (cohort 1; n = 16) and healthy controls (cohort 1 + 2; n = 73). Tox, Toxoplasmosis gondii.
Horizontal lines represent the group mean, and error bars indicate the 95% CI. Statistical analysis was performed on the transformed data set in
SPSS 25, and multiple comparison was performed by ANOVA followed by Dunnett’s T3 post hoc testing. *P < 0.05, ***P < 0.001.
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C1q deficiency and exacerbated IFN-a responses
have been reported.27 Moreover, C1q was noted
to inhibit immune complex-induced IFN-a
production by plasmacytoid dendritic cells, while
hepatitis C virus core protein was found to
downregulate inflammatory cytokine production
via C1q receptor (gC1qR) ligation.26,27,32 These
findings indicate that C1q-gC1qR interactions may
regulate cytokine responses, including IFN-a.
Therefore, we determined the relation between
serum C1q levels and type-1 IFN signature scores
in active TB disease, as both have been proposed
as biomarker to identify active TB. We observed a
clear inverse correlation between serum C1q levels
and type-1 IFN signature scores in APTB patients,
indicating that both these proposed biomarkers
for active TB disease can be mutually exclusive.
We propose that the combined measurement of
type-1 IFN signature and serum C1q may provide
added value in the diagnosis of active TB disease.
Positive blood type-1 IFN gene signatures also
occur in substantial numbers of patients with
systemic autoimmune disease, including pSS, SLE
or SSc.28–31 We did not observe a correlation
between the disease-specific type-1 IFN gene
signature score and serum C1q level in systemic
autoimmune disease (pSS, SLE or SLE). Several
studies did identify transcriptional differences, as
well as similarities, in type-1 IFN-inducible gene
signatures between various autoimmune diseases,
TB, and normal immune responses, supporting the
use of disease-specific IFN gene signatures.33,34
Thus, although the genes underlying the type-1
IFN gene signature differed between our TB
cohort and the systemic autoimmune disease
cohort, our data support a role for C1q in
regulating type-1 IFN signalling during active TB
disease. How this relates to disease pathology,
duration, activity or progression is still unclear
and should be investigated in future studies.
Interestingly, APTB patients with uveitis
displayed higher serum C1q levels than APTB
patients without uveitis. The exact reason for this
is currently unknown. However, C1q can modulate
T-cell responses by attenuating the activity of
CD8+ T cells, Th1 and Th17 cells and enhancing
regulatory T-cell activity.35,36 Furthermore, serum
analysis of rhesus macaques with pulmonary TB
revealed a further increase in serum C1q level in
those macaques that were unable to control
disease, while levels remained stable at pre-
infection levels in macaques that did control the
infection.23,37 This further supports a potential
immune dampening effect of C1q that hampers
Mtb control (within the lungs), thereby leading to
pulmonary disease progression and potential
systemic Mtb spread. Moreover, increased serum
C1q levels, during TB infection, are accompanied
by an increase in the expression of SERPING1, the
main inhibitor of the C1-complex.23,38 This may
suggest the presence of a TB-specific immune-
escape mechanism in which the immune-
suppressive effect of C1q on T-cell biology is
achieved without increased classical complement
pathway activation. At the same time, immune
dampening by C1q might limit immunopathology,
which might be beneficial at vital and vulnerable
anatomical locations such as the eyes.
Previously, we did not observe increased
expression of C1QA, C1QB or C1QC mRNA
transcripts in Mtb-infected RPE cells.39 This
suggests that Mtb-infected RPE cells most likely do
not directly contribute to the high serum C1q
levels we observed in TB-associated uveitis.
Potentially, RPE-derived molecules stimulate other
cell types (e.g. monocytes, macrophages and/or
dendritic cells) within and/or outside the eye to
produce C1q. Transcriptional and immuno-
histochemical analysis on enucleated eye
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Figure 6. Application of serum C1q and type-1 IFN signature score
to QFT+ patients with uveitis of unknown cause. The type-1 IFN
signature score cut-off value is indicated by the vertical line, and the
serum C1q level cut-off value is indicated by the horizontal line. From
the QFT+ patients with uveitis of unknown cause (cohort 1; n = 58),
30 patients located to quadrant IV (normal serum C1q and a negative
type-1 IFN signature) and might be considered as unlikely to suffer
from uveitis because of active TB. Five patients located to quadrant I,
six patients located to quadrant II, and 17 patients located to
quadrant III. The patients within quadrants I, II and III are more likely
to suffer from uveitis because of active TB.
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structures of patients suffering from TB-associated
uveitis would be of great interest to identify any
C1q-producing cells in the eye.
Swift diagnosis of TB-associated uveitis is crucial
to minimise disease burden and optimise
treatment outcome.10 However, QFT and TST do
not discriminate between a current active Mtb
infection and past exposure. Moreover, especially
in TB-endemic countries, the association between
a positive QFT and/or TST test with uveitis might
be coincidental. In such areas, over-diagnosis of
active TB-associated uveitis is a recognised
problem that may result in overzealous treatment
of QFT+ uveitis patients with highly toxic anti-TB
drugs.40 This underlines the need for new
biomarkers, or combinations thereof, to stratify
especially QFT+ patients with uveitis of unknown
cause, into those that are less likely, or highly
likely, to suffer from uveitis because of an active
Mtb infection.41–44 Previously, we proposed that
QFT+ uveitis patients with a negative type-1 IFN
signature had a low risk of suffering from uveitis
because of an active TB infection.22 However, our
current data indicate that active TB can exist in
the context of a negative type-1 IFN signature, in
the presence of elevated serum C1q levels.
Therefore, based on our current finding, we
propose that QFT+ patients with uveitis of
unknown cause, that have a negative type-1 IFN
signature and normal serum C1q levels (quadrant
IV, Figure 6), are least likely to suffer from uveitis
because of an active TB infection. These patients
might, for instance, suffer from autoimmune
uveitis, either related or unrelated to past Mtb
infection, or from uveitis of another (unidentified)
cause.45,46 In contrast, TB-associated uveitis is
highly likely in patients falling into one of the
other quadrants (quadrants I, II and III; Figure 6).
Combined type-1 IFN signature and serum C1q
measurement could therefore aid in the
diagnostic workup of QFT+ uveitis patients to
optimise treatment choice and potentially prevent
unnecessary treatment with highly toxic anti-TB
drugs in a substantial number of patients
(quadrant IV; Figure 6).
A limitation of our study is that we had no data
on outcome/treatment response available. Such
data would have been of additional value to
further support our hypothesis that QFT+ uveitis
patients that fall into quadrants I, II or III are
likely to display a beneficial response to ATT,
while patients falling into quadrant IV most likely
do not. Therefore, studies that explore the
relation between peripheral blood type-1 IFN
signature and serum C1q level in relation to the
efficacy of ATT in QFT+ uveitis patients are
warranted.
In conclusion, in this study we confirm the
recently published association between active TB
disease and elevated serum C1q levels. Our study
is the first to reveal an inverse correlation
between serum C1q level and type-1 IFN signature
score in active TB disease. Importantly, our data
clearly demonstrate that increased serum C1q
levels or a positive type-1 IFN signature are
individually not sufficient to detect active TB
disease. We propose that the combined
measurement of peripheral blood type-1 IFN
signature and serum C1q level is of added value
in the diagnosis of active TB disease. This is
further supported by ROC analysis on cohort 1,
where predicted probabilities calculated by binary
logistic regression on the combined measurement
of serum C1q and type-1 IFN signature score
yielded a sensitivity of 100% and specificity of
87%, thus outperforming the diagnostic accuracy
of serum C1q or type-1 IFN signature score alone
(Supplementary figure 2). However, additional
studies using higher numbers of patients are
required to confirm this observation.
Moreover, we expect that combined
measurement of both these biomarkers will
improve the stratification of patients that are
suspected of active TB-associated uveitis into
groups with either a low or high risk of having
uveitis because of an active TB infection. Such a
stratification could form the basis for future
diagnostic and treatment studies in QFT+ uveitis
patients.
METHODS
Patients and controls
Sera from three previously collected cohorts, two TB
cohorts from Indonesia (from now on designated as cohort
147 and 248) and one cohort consisting of systemic
autoimmune patients from mainly Caucasian origin (from
now on designated as cohort 328–30), were included in this
study. All individuals from cohorts 1 and 3 and all TB
patients from cohort 2 were HIV negative, and healthy
controls from cohort 2 were largely untested. A detailed
description of the patient cohorts is given in Table 1. All
included individuals provided their written informed
consent. The study was approved by the local medical ethics
committees of the Faculty of Medicine University of
Indonesia (cohort 1, FMUI: 268/H2.F1/ETIK/2014), The
Eijkman Institute research ethics committee, Jakarta (cohort
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248), and Erasmus MC, University Medical Center,
Rotterdam, the Netherlands (cohort 3, MEC-2011-116). This
study was conducted in coherence with the tenets of the
Declaration of Helsinki.
Tuberculosis, QFT+ uveitis and QFT uveitis
Cohort 1 was previously described and originates from
Jakarta (n = 131 patients and n = 23 healthy controls47).
Cohort 1 contained 10 sputum smear-positive APTB patients
without uveitis, 12 clinically diagnosed APTB patients with
uveitis of whom two were sputum smear positive, 58
QuantiFERON-Tb Gold test (QFT)-positive (> 0.35 IU mL1)
uveitis patients without any signs of active TB and no
alternative determined uveitis cause, 51 QFT uveitis
patients [infectious origin (n = 19), related to systemic
disease (n = 5), ocular syndromes (n = 12) or uveitis of
unknown aetiology (n = 15)], and 23 healthy Indonesian
controls. Cohort 2 also originates from Jakarta and
consisted of 50, sputum smear and culture positive, APTB
patients and 50 healthy Indonesian controls. Diagnostic
information concerning the presence of uveitis in these
patients was not available.48
Systemic autoimmune disease
Cohort 3 consists of sera from patients with pSS (n = 86),
SLE (n = 30) and SSc (n = 23) that were included at the
Erasmus MC, University Medical Center, Rotterdam, the
Netherlands.
Serum C1q ELISA
Serum C1q levels were determined by ELISA, as described
previously.23,49 In short, MaxiSorp (Nunc, Rochester, NY,
USA) plates were coated overnight at 4°C with mouse anti-
human C1q antibody (Department of Nephrology, Leiden
University Medical Center, the Netherlands) in coating
buffer (0.1 m Na2CO3, 0.1 m NaHCO3, pH 9.6). The next
day, plates were washed and blocked with PBS/1% BSA for
1 h at 37°C. After washing, the plates were incubated for
1 h at 37°C with serum samples serially diluted in PBS/1%
BSA/0.05% Tween. Subsequently, the plates were washed
and incubated (1 h, 37°C) with rabbit anti-human C1q
antibody (DAKO, Jena, Germany). Hereafter, the plates
were washed and incubated (1 h, 37°C) with horseradish
peroxidase (HRP)-labelled goat-anti-rabbit antibody
(DAKO). As substrate, 2,2’-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTS; Sigma, Saint Louis, MO, USA) was
used to optically visualise HRP activity, which was
quantified by measuring the optical density at 415 nm.
Wash steps were performed with PBS/0.05% Tween. All
serum sample measurements within the linear range of the
reference curve were averaged, and reference curve
dilutions were analysed in duplicate.
Peripheral blood type-1 IFN gene signatures
From patients and healthy controls included in cohort 1,
the TB-related peripheral blood type-1 IFN gene signature
scores were previously determined in blood obtained at the
same time as serum used for C1q analysis in our current
study.22 In addition, from cohort 3, the systemic
autoimmune disease-related peripheral blood type-1 IFN
signature scores were available and determined as
previously described.28–30 Genes comprising the disease-
related type-1 IFN signatures, as well as the formula used to
calculate the type-1 IFN signature score, are provided in
Supplementary table 1.
Statistical analysis
Data distribution of all groups was determined with the
D’Agostino–Pearson normality test. As most of the data
were not normally distributed within the groups, a log
transformation was applied on the complete data set. C1q
values were transformed by log (C1q µg mL1), while the
type-1 IFN signature scores were transformed by log
(15 + type-1 IFN signature).
Table 1. Patient characteristics
(Sub)Group
Mean Age
(SD)
Male-to-Female
ratio
Sputum
positive
QFT positive
(> 0.35 IU mL1)
Type I IFN signature
score positive (> 5.6)
Cohort 1 (n = 154)
Healthy Control (n = 23) 31.0 (9.4) 0.4 n/a 0/23 2/23
APTB w/o uveitis (n = 10) 41.3 (15.7) 2.3 10/10 7/10 10/10
APTB-assoc. uveitis (n = 12) 42.0 (17.2) 2.0 2/12 10/12 5/12
QFT+ Uveitis of unknown aetiology (N = 58) 46.3 (13.2) 0.4 n/a 58/58 23/58
QFT Uveitis (N = 51) 39.9 (16.5) 1.6 n/a 0/51 21/58
Cohort 2 (n = 100)
Healthy Control (n = 50) 34.6 (12.6) 0.9 0/50 n/a n/a
APTB uveitis unknown (n = 50) 31.4 (9.5) 2.1 50/50 n/a n/a
Cohort 3 (n = 139)
Primary Sj€ogren’s syndrome (n = 86) 60.2 (13.2) 0.1 n/a n/a n/a
Systemic lupus erythematosus (n = 30) 46.8 (13.6) 0.1 n/a n/a n/a
Systemic sclerosis (n = 23) 59.5 (10.9) 0.2 n/a n/a n/a
APTB, active pulmonary tuberculosis; IFN, interferon; QFT, QuantiFERON-TB Gold test; SD, standard deviation.
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Comparison between two groups was performed with an
unpaired Student’s t-test. If group variances differed
significantly (F-test), an unpaired Welch’s t-test was used
instead. Correlations were determined with Pearson’s r test.
Multiple comparison testing was performed by analysis of
variance (ANOVA) followed by Dunnett’s T3 post hoc
testing. Statistical analysis was performed in GraphPad
Prism 5.0 and SPSS 25. A P-value < 0.05 was considered
significant.
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